XML 37 R31.htm IDEA: XBRL DOCUMENT v3.25.3
Balance Sheet Components (Tables)
9 Months Ended
Sep. 30, 2025
Balance Sheet Related Disclosures [Abstract]  
Schedule of Inventory

Inventory consisted of the following:

 

 

 

September 30,

 

 

December 31,

 

(in thousands)

 

2025

 

 

2024

 

Raw materials

 

$

14,373

 

 

$

11,113

 

Work-in-process

 

 

18,671

 

 

 

20,529

 

Finished goods

 

 

5,319

 

 

 

2,083

 

Total inventory

 

$

38,363

 

 

$

33,725

 

Schedule of Other Accrued Liabilities

Other accrued liabilities consisted of the following:

 

 

 

September 30,

 

 

December 31,

 

(in thousands)

 

2025

 

 

2024

 

Accrued contract manufacturing expenses

 

$

1,128

 

 

$

1,071

 

Accrued clinical and research expenses

 

 

179

 

 

 

611

 

Accrued professional services

 

 

5,683

 

 

 

8,682

 

Current portion of lease liabilities

 

 

680

 

 

 

1,572

 

Royalty obligation payable

 

 

3,434

 

 

 

2,951

 

Current portion of deferred royalty obligations

 

 

7,742

 

 

 

6,438

 

Accrued license fees and royalties

 

 

1,556

 

 

 

1,727

 

Other(1)

 

 

1,205

 

 

 

6,947

 

Total other accrued liabilities

 

$

21,607

 

 

$

29,999

 

 

(1) Amount as of December 31, 2024 includes $5.3 million advance payments received from our partner for inventory supply as discussed in Note 4, “License and Collaboration Arrangements”.

Schedule of Other Long-term Liabilities

Other long-term liabilities consisted of the following:

 

 

 

September 30,

 

 

December 31,

 

(in thousands)

 

2025

 

 

2024

 

Long-term portion of deferred royalty obligation

 

$

56,526

 

 

$

63,096

 

Long-term portion of lease liabilities

 

 

905

 

 

 

1,179

 

Total other long-term liabilities

 

$

57,431

 

 

$

64,275